Hi CH,
Elan/Janssen's Bapinuzumab did the same as BIIB's drug (target the A-Beta and remove it), had the same side effects, and did not show efficacy. This is just a rehash of the Bapinuzumab mode of action with the same side-effect profile. PRAN's Pbt2 restores the metals homeostasis, has antibiotic properties, has shown to increase dentritic density in-vivo and is neuro-protective. I think the PCH delays the development of a first-in-class AND best-in-Class treatment for two incurable neuro-degenerative diseases which at best is a result of ignorance on the part of the FDA and at worst is a criminal act. The ones that suffer are the patients. IMHO
Best Regards,
Simon
Paper Alert: Aducanumab Phase 1b Study Published, page-9
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $18.45K | 6.153M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 112553933 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 140078273 | 50 |
View Market Depth
| Last trade - 11.42am 18/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |